Literature DB >> 27075126

Acute generalized exanthematous pustulosis associated with primary Epstein-Barr virus infection.

Nolwenn Ropars1, Laure Darrieux1, Laurent Tisseau2, Gilles Safa1.   

Abstract

Entities:  

Keywords:  AGEP, Acute generalized exanthematous pustulosis; EBV, Epstein-Barr virus; Epstein-Barr virus; acute generalized exanthematous pustulosis; children

Year:  2014        PMID: 27075126      PMCID: PMC4802527          DOI: 10.1016/j.jdcr.2014.09.004

Source DB:  PubMed          Journal:  JAAD Case Rep        ISSN: 2352-5126


× No keyword cloud information.
Acute generalized exanthematous pustulosis (AGEP) is a rare severe cutaneous reaction characterized by the acute onset of generalized nonfollicular sterile pustules arising on an edematous erythema. The eruption is usually associated with fever and neutrophilic leukocytosis. Although AGEP is precipitated by drugs in most cases, there have been isolated reports of AGEP associated with infections (parvovirus B19, cytomegalovirus, coxsackie B4, Mycoplasma pneumoniae), mercury exposure, and spider bites.2, 3, 4, 5 Herein, we report the occurrence of AGEP possibly triggered by an acute primary Epstein-Barr virus (EBV) infection in a 16-year-old girl.

Case report

The girl presented to the emergency department with a 3-day history of a generalized pruritic eruption of abrupt onset. She complained of fever (39.4°C) and chills in addition to a sore throat and fatigue. She denied taking any medications before the skin eruption occurred, and she had no personal or family history of skin disease. Physical examination found erythematous and edematous patches, with numerous nonfollicular pustules on the face, trunk, and extremities (Fig 1). The patient had minimal pharyngeal erythema and enlarged cervical lymph nodes. The remainder of the examination findings were normal.
Fig 1

Acute generalized exanthematous pustulosis. Erythematous and edematous eruption, with numerous pinpoint pustules on the dorsum of the hand.

Laboratory studies found marked leukocytosis of 19100/μL, with neutrophilia (9220/μL; normal, 1800-7500/μL), eosinophilia (2670/μL; normal, <800/μL), lymphocytosis (5520/μL; normal, 1000-4000/μL), monocytosis (1580/μL; normal, <1000/μL), and an elevated C-reactive protein level (38.5 mg/L; normal, <10 mg/L). Liver function test results and urea and creatinine levels were within the normal limits. Blood, urine, and pustule cultures for bacteria were negative. Serologic tests for parvovirus B19, enterovirus, cytomegalovirus, hepatitis A virus, hepatitis B virus, hepatitis C virus, human immunodeficiency virus, and toxoplasmosis were all negative. EBV serologic test result was positive for immunoglobulin M against viral capsid antigen, consistent with an acute EBV infection. A skin biopsy found spongiform subcorneal and intraepidermal neutrophilic pustules along with papillary dermal edema, superficial lymphocytic infiltrate with neutrophils, and focal necrosis of keratinocytes (Fig 2). According to the EuroSCAR study group criteria, our patient had a score of 11, indicating a definite diagnosis of AGEP. The patient was then treated symptomatically with topical corticosteroids and emollients, resulting in rapid resolution of the rash within 2 weeks followed by a postpustular desquamation (Fig 3).
Fig 2

Acute generalized exanthematous pustulosis. A skin biopsy shows a subcorneal pustule filled with neutrophils. Note the presence of necrotic keratinocytes in the epidermis. Papillary dermal edema and superficial mixed infiltrate composed of lymphocytes and neutrophils can also be seen. (Hematoxylin-eosin stain; original magnification: ×200.)

Fig 3

Acute generalized exanthematous pustulosis. Typical superficial postpustular desquamation after 2 weeks.

Discussion

AGEP is a rare acute pustular reaction that is most often caused by drugs. It is a self-limiting disease, usually arising rapidly, within 48 hours after drug exposure, and resolving quickly, within 2 weeks after withdrawal of the causative agent. In typical cases, the pustules are followed by characteristic postpustular pinpoint desquamation. According to the EuroSCAR study, antibiotics (such as aminopenicillins, pristinamycin, and quinolones), terbinafine, antimalarials, and calcium channel blockers (diltiazem) are the most frequently reported triggers of AGEP. The diagnostic criteria include an acute pustular eruption, fever (>38°C), blood neutrophilia (>7000/μL), spongiform subcorneal or intraepidermal pustules on skin biopsy, and acute evolution and spontaneous resolution of the pustules in less than 15 days. Our patient fulfilled the diagnostic criteria for AGEP (Table I). AGEP is, however, an uncommon condition in children, and certain investigators have suggested that viral infections might be the most frequent triggers in the pediatric population. The main differential diagnosis of AGEP is generalized pustular psoriasis. In our patient, the absence of a personal or family history of psoriasis, the acute course and rapid resolution of the rash, and the presence of necrotic keratinocytes on histologic examination supported a diagnosis of AGEP. Although the pathogenesis of AGEP is not well understood, it is postulated to include T cell–mediated neutrophilic inflammation involving drug-specific CD4+ T cells, cytotoxic CD8+ T cells, and inflammatory cytokines and chemokines. In immunocompetent patients, infectious mononucleosis represents a benign, self-limiting lymphoproliferative disorder characterized by primary EBV infection of B lymphocytes and massive proliferation of highly activated cytotoxic CD8+ T cells, believed to be responsible for the control of viral replication and the establishment of latency. In our patient, it might be hypothesized that this vigorous immune response to EBV by cytotoxic CD8+ lymphocytes triggered the appearance of AGEP. To the best of our knowledge, in addition to our case, there has been only one other reported case of AGEP associated with acute EBV infection. However, in that case, AGEP developed 4 days after starting treatment with amoxicillin/clavulanic acid, which represents the most likely inciting agent.
Table I

AGEP validation score of the EuroSCAR study group

Morphology
 Pustules
 Typical+2
 Compatible+1
 Insufficient0
Erythema
 Typical+2
 Compatible+1
 Insufficient0
Distribution/pattern
 Typical+2
 Compatible+1
 Insufficient0
Postpustular desquamation
 Yes+1
 No/insufficient0
Course
 Mucosal involvement
 Yes−2
 No0
Acute onset (<10 d)
 Yes0
 No−2
Resolution (<15 d)
 Yes0
 No−4
Fever (>38°C)
 Yes+1
 No0
PNN (>7000/μL)
 Yes+1
 No0
Histology
 Other disease−10
 Not representative/no histology0
 Exocytosis of PNN+1
 Subcorneal and/or intraepidermal non spongiform or NOS pustules with papillary edema or subcorneal and/or intraepidermal spongiform or NOS pustules without papillary edema+2
 Spongiform subcorneal and/or intraepidermal pustules with papillary edema+3

Interpretation: ≤0: no AGEP; 1-4: possible; 5-7: probable; 8-12: definite.

NOS, not otherwise specified; PNN, polymorphonuclear neutrophils.

Typical: typical morphology.

Compatible: not typical, but not strongly suggestive of other disease.

Insufficient: lesions cannot be judged.

The current case suggests that acute EBV infection should be considered as an additional trigger of AGEP, particularly in the pediatric population.
  9 in total

1.  Characterization of the expanded T cell population in infectious mononucleosis: apoptosis, expression of apoptosis-related genes, and Epstein-Barr virus (EBV) status.

Authors:  C S Verbeke; U Wenthe; W F Bergler; H Zentgraf
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

2.  Acute generalized exanthematous pustulosis in children.

Authors:  Sibel Ersoy; Amy S Paller; Anthony J Mancini
Journal:  Arch Dermatol       Date:  2004-09

Review 3.  Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern.

Authors:  A Sidoroff; S Halevy; J N Bavinck; L Vaillant; J C Roujeau
Journal:  J Cutan Pathol       Date:  2001-03       Impact factor: 1.587

4.  Mercury-induced acute generalized exanthematous pustulosis misdiagnosed as a drug-related case.

Authors:  Hichem Belhadjali; Selsabil Mandhouj; Adnene Moussa; Leila Njim; Montassar Amri; Abdelfattah Zakhama; Jameleddine Zili
Journal:  Contact Dermatitis       Date:  2008-07       Impact factor: 6.600

5.  Acute generalized exanthematous pustulosis with cytomegalovirus infection.

Authors:  V Haro-Gabaldón; J Sánchez-Sánchez-Vizcaino; P Ruiz-Avila; J Gutiérrez-Fernández; J Linares; R Naranjo-Sintes
Journal:  Int J Dermatol       Date:  1996-10       Impact factor: 2.736

6.  T-cell involvement in drug-induced acute generalized exanthematous pustulosis.

Authors:  M Britschgi; U C Steiner; S Schmid; J P Depta; G Senti; A Bircher; C Burkhart; N Yawalkar; W J Pichler
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

7.  Acute generalized exanthematous pustulosis following a spider bite: report of 3 cases.

Authors:  Batya B Davidovici; Dyachenko Pavel; Emanuela Cagnano; Dganit Rozenman; Sima Halevy
Journal:  J Am Acad Dermatol       Date:  2006-09       Impact factor: 11.527

8.  Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR).

Authors:  A Sidoroff; A Dunant; C Viboud; S Halevy; J N Bouwes Bavinck; L Naldi; M Mockenhaupt; J-P Fagot; J-C Roujeau
Journal:  Br J Dermatol       Date:  2007-09-13       Impact factor: 9.302

9.  Acute generalized exanthematous pustulosis. Analysis of 63 cases.

Authors:  J C Roujeau; P Bioulac-Sage; C Bourseau; J C Guillaume; P Bernard; C Lok; P Plantin; A Claudy; C Delavierre; L Vaillant
Journal:  Arch Dermatol       Date:  1991-09
  9 in total
  2 in total

1.  Severe Cutaneous Adverse Reactions: A Single-Center Retrospective Study of 173 Patients in China.

Authors:  Zhongyi Xu; Jie Shen; Yiwen Yang; Ruoyue Yuan; Leihong Flora Xiang; Chengfeng Zhang
Journal:  Ann Dermatol       Date:  2019-08-30       Impact factor: 1.444

2.  Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine.

Authors:  Samantha Haraszti; Selin Sendil; Nichole Jensen
Journal:  Am J Case Rep       Date:  2020-10-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.